Biopharmaceutical company: MacroGenics, Inc. (MGNX)

MacroGenics, Inc. (NASDAQ: MGNX), founded in 2000 and headquartered in Rockville, Maryland, USA, has 427 full-time employees Biopharmaceutical Company , found and developed antibody based therapies for cancer in the United States.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/mgnx.html

MacroGenics, Inc. (MGNX)

As a biopharmaceutical company, MacroGenics' professional team is committed to the discovery and development of innovative antibody based therapies aimed at regulating human immune response to treat cancer. The company's core scientific expertise is in the field of protein engineering, and its candidate products are mainly created through the company's proprietary protein engineering platform, including its DART ® Dual specificity and Fc optimization platform (DART ® Bispecific and Fc Optimization Platforms）。 The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/mgnx.html

These platforms are usually used for the production of antibodies, antibody derivatives and antibody like molecules, and are used as therapeutic agents. MacroGenics currently has a series of candidate products in human clinical trials, including nine immune oncology programs. MacroGenics's candidate products and platforms have been matched with the world's leading pharmaceutical and Biotechnology Company A variety of partnerships have been established, including: Incyte Corporation Les Laboratoires Servier and Institut de Recherches Servier and Zai Lab Limited Etc. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/mgnx.html

MacroGenics Immunooncology candidate product line includes: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/mgnx.html

• Margetuximab， A monoclonal antibody, which is in the phase III clinical trial, targeting HER2 expressing tumors, such as various breast cancer and gastroesophageal cancer.
• Flotetuzumab， A DART molecule that recognizes CD123 and CD3.
• MGA012， A monoclonal antibody against PD-1 that inhibits programmed cell death protein 1 (PD-1).
• MGD013， A monoclonal antibody against immune checkpoint PD-1 and lymphocyte activation gene 3.
• MGD019， A monoclonal antibody against PD-1, an immune checkpoint, and cytotoxic T-lymphocyte associated protein 4.
• Enoblituzumab， A monoclonal antibody targeting B7-H3.
• MGD009， A DART molecule that targets B7-H3 expressed on tumor cells and CD3.
• MGC018， An antibody drug conjugate that targets solid tumors expressing B7-H3.
• MGD007， A DART molecule that targets glycoproteins A33 and CD3.
• MGD014， A DART molecule that targets virus infected cells.

On March 9, 2023, MacroGenics (NASDAQ stock code: MGNX) said that it would sell the royalties of TZIELD's future global net sales to the wholly-owned subsidiary of DRI Healthcare Trust at a price of up to 200 million dollars. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/mgnx.html

MacroGenics, Inc. (MGNX) US equity investment